§ 13F · FUND PROFILE
Decheng Capital LLC.
Institutional filer · behavioral pattern: Other. Summary pending.
AUM · $396.0T (13F)Positions · 25Turnover · — · Q4Filed · Feb 12, 2026
CONCENTRATION
—
Top 10 holdings
NEW BUYS
0
+$743.4T deployed
EXITS
0
No exits
SECTOR SHIFT
—
No prior quarter data
3YR HIT RATE
—
Top-5 overlap
§ 01 · TOP HOLDINGS
The book · Q4 2025
FILED FEB 12, 2026
| # | Ticker | Name | Shares | $ value | % port | Δ Q4 |
|---|---|---|---|---|---|---|
| 1 | CGON | CG ONCOLOGY INC | 6.37M | $264.6T | 35.6% | NEW |
| 2 | NUVB | Nuvation Bio Inc. | 25.95M | $232.6T | 31.3% | NEW |
| 3 | UPB | Upstream Bio Inc. | 3.14M | $85.3T | 11.5% | NEW |
| 4 | AARD | AARDVARK THERAPEUTICS INC | 3.92M | $51.4T | 6.9% | NEW |
| 5 | LYEL | Lyell Immunopharma, Inc. | 692K | $21.3T | 2.9% | NEW |
| 6 | NAMS | NEWAMSTERDAM PHARMA CO NV | 592K | $20.8T | 2.8% | NEW |
| 7 | RVMD | REVOLUTION MEDICINES INC(NSM) | 200K | $15.9T | 2.1% | NEW |
| 8 | RCUS | Arcus Biosciences, Inc | 542K | $12.9T | 1.7% | NEW |
| 9 | ACRS | Aclaris Therapeutics, Inc. | 4.04M | $12.2T | 1.6% | NEW |
| 10 | EQ | Equillium Inc. | 4.45M | $6.9T | 0.9% | NEW |
§ 02 · SECTOR ALLOCATION
Where the money is
Sector data pending
§ 03 · THE DECHENG SIGNAL
AC read
Decheng Capital LLC is a Other fund managing $395968.0 trillion in assets. The fund runs a focused portfolio of just 25 positions.
Read the full dossier →§ 04 · FILING HISTORY
Q-by-Q deltas
1 FILINGS
Q4 2025
Steady book
+0 buys · −0 exits · 0 changed
Q2 2025
Steady book
+0 buys · −0 exits · 0 changed
Q1 2025
Steady book
+0 buys · −0 exits · 0 changed